[1]
Lucioni, C., Mazzi, S. and Caporali, R. 2015. Budget impact analysis of infliximab biosimilar: the Italian scenery: Analisi di budget impact del biosimilare di infliximab: lo scenario italiano. Global and Regional Health Technology Assessment. 2, 2 (Oct. 2015), 78–88. DOI:https://doi.org/10.33393/grhta.2015.330.